Enliven Therapeutics(ELVN.US)

Company Encyclopedia
View More
name
Enliven Therapeutics
ELVN.US
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
4.691 T
ELVN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares

    Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported the sale of common shares of the company. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.

    Reuters·
    US
    ELVN
    +0.45%
    Reuters·
    US
    ELVN
    +0.45%

    Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial

    Enliven Therapeutics (ELVN) has appointed Richard Fair as CEO, while co-founder Sam Kintz shifts to Head of Pipeline. The stock has faced a decline, with a 7-day return of -22.7% and a 1-year return of -27.17%. Despite this, the price-to-book ratio of 2.1x suggests undervaluation compared to peers. However, clinical setbacks could affect this narrative. Investors are advised to explore other biotech opportunities and consider risks and rewards in their investment decisions.

    Simplywall·
    US
    ELVN
    +0.45%
    Simplywall·
    US
    ELVN
    +0.45%

    Enliven Therapeutics (Nasdaq: ELVN) grants inducement for small molecule therapeutics development.

    Boulder, Colorado, Dec. 11, 2025 - Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company traded on Nasdaq under the symbol ELVN, revealed today that they have awarded a significant grant on the same date. Enliven is dedicated to identifying and advancing small molecule therapeutics.

    Unusual Whales·
    US
    ELVN
    +0.45%
    Unusual Whales·
    US
    ELVN
    +0.45%

    Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling

    Enliven Therapeutics (NASDAQ:ELVN) shares fell 6.5% after COO Anish Patel sold 6,663 shares. The stock traded as low as $19.36, with a significant drop in trading volume. Despite the decline, analysts maintain a "Moderate Buy" rating with a target price of $41.20. Institutional investors have been adjusting their positions, with significant inflows from hedge funds. Enliven focuses on developing small molecule inhibitors for cancer treatment, with key products in clinical trials.

    Market Beat·
    US
    ELVN
    +0.45%
    Market Beat·
    US
    ELVN
    +0.45%

    Enliven Therapeutics Names Rick Fair CEO

    Enliven Therapeutics Inc. has appointed Rick Fair as CEO and Board member, effective December 11, 2025. Co-founder Sam Kintz will become Head of Pipeline. This announcement was originally published by Enliven Therapeutics via PR Newswire.

    Reuters·
    US
    ELVN
    +0.45%
    Reuters·
    US
    ELVN
    +0.45%
    © 2026 Longbridge｜Disclaimer